We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Prestige Consumer Healthcare (PBH) Q4: Wall Street Projections for Key Metrics
Read MoreHide Full Article
The upcoming report from Prestige Consumer Healthcare (PBH - Free Report) is expected to reveal quarterly earnings of $1.30 per share, indicating an increase of 27.5% compared to the year-ago period. Analysts forecast revenues of $288.95 million, representing an increase of 4.3% year over year.
Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Prestige Consumer Healthcare metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus among analysts is that 'Revenues- OTC Healthcare- International' will reach $47.57 million. The estimate indicates a year-over-year change of +3.7%.
Analysts forecast 'Revenues- OTC Healthcare- North American' to reach $241.66 million. The estimate suggests a change of +4.6% year over year.
Analysts predict that the 'Gross profit- OTC Healthcare- North American' will reach $136.93 million. Compared to the current estimate, the company reported $125.40 million in the same quarter of the previous year.
The average prediction of analysts places 'Gross profit- OTC Healthcare- International' at $28.03 million. The estimate is in contrast to the year-ago figure of $26.42 million.
Shares of Prestige Consumer Healthcare have experienced a change of +1.5% in the past month compared to the +10.6% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), PBH is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into Prestige Consumer Healthcare (PBH) Q4: Wall Street Projections for Key Metrics
The upcoming report from Prestige Consumer Healthcare (PBH - Free Report) is expected to reveal quarterly earnings of $1.30 per share, indicating an increase of 27.5% compared to the year-ago period. Analysts forecast revenues of $288.95 million, representing an increase of 4.3% year over year.
Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Prestige Consumer Healthcare metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus among analysts is that 'Revenues- OTC Healthcare- International' will reach $47.57 million. The estimate indicates a year-over-year change of +3.7%.
Analysts forecast 'Revenues- OTC Healthcare- North American' to reach $241.66 million. The estimate suggests a change of +4.6% year over year.
Analysts predict that the 'Gross profit- OTC Healthcare- North American' will reach $136.93 million. Compared to the current estimate, the company reported $125.40 million in the same quarter of the previous year.
The average prediction of analysts places 'Gross profit- OTC Healthcare- International' at $28.03 million. The estimate is in contrast to the year-ago figure of $26.42 million.
View all Key Company Metrics for Prestige Consumer Healthcare here>>>
Shares of Prestige Consumer Healthcare have experienced a change of +1.5% in the past month compared to the +10.6% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), PBH is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>